5

ABSTRACT

The invention relates to a pharmaceutical formulation comprising a LTB₄ antagonist having a hydroxy and a benzamidine group or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, in particular a compound of formula (I)

$$A \longrightarrow A \longrightarrow C \longrightarrow NH_2$$

$$N-R$$
(I)

wherein R and A are as defined in the claims, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof (1) and at least one cyclooxygenase-2 inhibitor, a combined cox1/2 inhibitor or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof (2), and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.